Abstract: A pole step apparatus for fiberglass utility poles can have a supporting body is disclosed, having a bended portion with a brace on the supporting body; a grip surface distal to the bended portion; a nut on a threaded portion of the supporting body to tighten the brace toward the bended portion via the threaded portion of the supporting body; a passthrough in the brace formed can accommodate a supporting body and resists rotation; the bended portion is formed on the supporting body at a 90-degree angle; an arc is formed on the brace adjacent to the bended portion; and the brace resists rotation via a non-cylindrical, anti-rotational portion of the supporting body.

Abstract: The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment of diseases involving mucin, especially mucin secreting cancers, or diseases involving blood clots (thrombi).

Abstract: The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment of diseases involving mucin, especially mucin secreting cancers, or diseases involving blood clots (thrombi).

Abstract: The present invention relates to synergistic compositions comprising bromelain, or a proteolytic fraction thereof, and cysteamine or a metabolite, pharmaceutically acceptable salt, solvate or prodrug thereof The invention also relates to methods and uses of such compositions for the treatment of diseases involving mucin.

Abstract: A pole step apparatus for fiberglass utility poles can have a supporting body is disclosed, having a bended portion with a brace on the supporting body; a grip surface distal to the bended portion; a nut on a threaded portion of the supporting body to tighten the brace toward the bended portion via the threaded portion of the supporting body; a passthrough in the brace formed can accommodate a supporting body and resists rotation; the bended portion is formed on the supporting body at a 90-degree angle; an arc is formed on the brace adjacent to the bended portion; and the brace resists rotation via a non-cylindrical, anti-rotational portion of the supporting body.

Abstract: The present invention relates to synergistic compositions comprising bromelain, or a proteolytic fraction thereof, and cysteamine or a metabolite, pharmaceutically acceptable salt, solvate or prodrug thereof The invention also relates to methods and uses of such compositions for the treatment of diseases involving mucin.

Abstract: The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.

Abstract: A seismic resistant cluster bracket for mounting to an electrical power-line pole and supporting power distribution transformers includes a rectangular support frame which has upper and lower horizontal cross beams secured to left, right, and center vertical strong-back struts. Pole-mount brackets protruding rearward from the center strong-back are provided with bolt holes for receiving bolts to attach the support frame to a power pole. Top and bottom safety mount brackets, each having vertical stabilizer ribs for engaging indentations of a rear transformer bracket are attached to the front of each strong-back. A pair of adjustable extension length diagonal braces spaced equal distances laterally outwards from the center strong-back are pivotal mounted to the rear side of the support frame, extendable to adjustable lengths and boltable to a power pole to secure the frame against movements relative to the power pole as a result of static weight loading or seismic vibrations.

Abstract: The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.

Abstract: The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.

Abstract: A tissue ablation system including numerous components and methods is described herein for encircling target tissue and generating tissue ablation volumes in various biological tissues. The biological tissue includes tissue of a variety of organs of the human body including the liver, spleen, kidney, lung, breast and other organs, but is not so limited. The tissue ablation device comprises an energy source and at least one trocar coupled to the energy source, the trocar having a body, a proximal end, and a distal end. The trocar carries an electrode array that comprises a plurality of electrodes, each electrode of the plurality of electrodes is configured to extend from the trocar when moved from a retracted state to a deployed state, and to have at least one radius of curvature in the deployed state so that the electrode array forms a series of shaped electrodes in the deployed state.

Abstract: Energy delivery systems and methods are provided for use in biological tissue. The energy delivery system includes an energy source and an electrode array. The electrode array includes bipolar electrodes positioned so a first spacing between a pair of adjacent electrodes is different relative to a second spacing between at least one other pair of adjacent electrodes. The electrode array and the energy source are coupled and configured to generate uniform energy density in target tissue according to impedance of the target tissue.

Abstract: The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment of diseases involving mucin, especially mucin secreting cancers, or diseases involving blood clots (thrombi).

Abstract: A tissue ablation system including numerous components and methods is described herein for encircling target tissue and generating tissue ablation volumes in various biological tissues. The biological tissue includes tissue of a variety of organs of the human body including the liver, spleen, kidney, lung, breast and other organs, but is not so limited. The tissue ablation device comprises an energy source and at least one trocar coupled to the energy source, the trocar having a body, a proximal end, and a distal end. The trocar carries an electrode array that comprises a plurality of electrodes, each electrode of the plurality of electrodes is configured to extend from the trocar when moved from a retracted state to a deployed state, and to have at least one radius of curvature in the deployed state so that the electrode array forms a series of shaped electrodes in the deployed state.

Abstract: The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.

Abstract: Energy delivery systems and methods are provided for use in biological tissue. The energy delivery system includes an energy source and an electrode array. The electrode array includes bipolar electrodes positioned so a first spacing between a pair of adjacent electrodes is different relative to a second spacing between at least one other pair of adjacent electrodes. The electrode array and the energy source are coupled and configured to generate uniform energy density in target tissue according to impedance of the target tissue.

Abstract: The present invention provides methods for inhibiting VEGF production or secretion in a subject comprising administering to the subject an effective amount of a compound of Formula I. The invention also provides methods for the treatment or prevention of conditions associated with abnormal levels of VEGF production or secretion.

Abstract: A tissue ablation device and method for tissue ablation are described. The tissue ablation device comprises an energy source and an introducer coupled to the energy source, the introducer having a body, a proximal end, and a distal end. The introducer carries an electrode array that comprises a plurality of electrodes, each electrode of the plurality of electrodes is configured to extend from the body of the introducer when moved from a retracted state to a deployed state. The electrode array is designed to encircle a portion of a target tissue when the electrodes are extended into the deployed state and to form a relatively spherical shaped ablation pattern in a tissue volume surrounding the target tissue when energized by the energy source.

Abstract: The present invention provides methods for the treatment of tumors, comprising administration of an effective amount of at least one taxoid and an effective amount of at least one benzimidazol carbamate compound of formula (I). The invention also provides a method for the treatment of tumors insensitive to one or more anti-mitotic drugs, the method comprising administering a effective amount of at least one benzimidazole carbamate compound of formula (I). Also provide are compositions for carrying out methods of the invention.

Abstract: A method and system for determining reporting the location of an originating telephone device. A location interoperability platform receives a signaling message from a switch, reflecting a call request from an originating device and carrying data indicating whether the originating device is a landline device or a wireless device. If the data indicates that the originating device is a landline device, then the location interoperability platform invokes a landline location-determination process to determine the location of the originating device. On the other hand, if the data indicates that the originating device is a wireless device, then the location interoperability platform invokes a wireless location-determination process to determine the location of the originating device. The location interoperability platform may then report the determined location to the called party, to help facilitate a location-based service such as emergency response.